Skip to content
About Us
Our Company
Our Team
Directors
Contact
Our Science
VAAST Platform
Mucosal Immunity
Platform Difference
Pipeline
COVID-19
Norovirus
Influenza
HPV
Publications
Investors
Careers
Vaxart Guiding Principles
Benefits
Open Positions
Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate
April 30, 2025
Vaxart to Present at World Vaccine Congress Washington 2025 on April 23
April 16, 2025
Vaxart Provides Business Update and Reports Full Year 2024 Financial Results
March 20, 2025
Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20
March 13, 2025
Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate
March 11, 2025
Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults
March 5, 2025
Vaxart Appoints Seasoned Biotech Executive Kevin Finney to Board of Directors
January 28, 2025
Vaxart Highlights Progress of COVID-19, Norovirus and Influenza Programs
January 14, 2025
Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial
January 13, 2025
